Search

Your search keyword '"Urata, Tomohiro"' showing total 33 results
Start Over Author "Urata, Tomohiro"
33 results on '"Urata, Tomohiro"'

1. Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study

Author

Urata, Tomohiro, Naoi, Yusuke, Jiang, Aixiang, Boyle, Merrill, Sunami, Kazutaka, Imai, Toshi, Nawa, Yuichiro, Hiramatsu, Yasushi, Yamamoto, Kazuhiko, Fujii, Soichiro, Yoshida, Isao, Yano, Tomofumi, Chijimatsu, Ryota, Murakami, Hiroyuki, Ikeuchi, Kazuhiro, Kobayashi, Hiroki, Tani, Katsuma, Ujiie, Hideki, Inoue, Hirofumi, Tomida, Shuta, Yamamoto, Akira, Kondo, Takumi, Fujiwara, Hideaki, Asada, Noboru, Nishimori, Hisakazu, Fujii, Keiko, Fujii, Nobuharu, Matsuoka, Ken-ichi, Sawada, Keisuke, Momose, Shuji, Tamaru, Jun-ichi, Nishikori, Asami, Sato, Yasuharu, Yoshino, Tadashi, Maeda, Yoshinobu, Scott, David W., and Ennishi, Daisuke

Published
2023
Full Text
View/download PDF

3. Collection efficiency and safety of large‐volume leukapheresis for the manufacturing of tisagenlecleucel

Author

Kitamura, Wataru, primary, Urata, Tomohiro, additional, Fujii, Keiko, additional, Fukumi, Takuya, additional, Ikeuchi, Kazuhiro, additional, Seike, Keisuke, additional, Fujiwara, Hideaki, additional, Asada, Noboru, additional, Ennishi, Daisuke, additional, Matsuoka, Ken‐ichi, additional, Otsuka, Fumio, additional, Maeda, Yoshinobu, additional, and Fujii, Nobuharu, additional

Published
2024
Full Text
View/download PDF

4. Evaluating the efficiency and safety of large‐volume leukapheresis using the Spectra Optia continuous mononuclear cell collection protocol for peripheral blood stem cell collection from healthy donors: A retrospective study

Author

Sumii, Yuichi, primary, Fujii, Keiko, additional, Kondo, Takumi, additional, Urata, Tomohiro, additional, Kimura, Maiko, additional, Fujiwara, Hideaki, additional, Asada, Noboru, additional, Ennishi, Daisuke, additional, Nishimori, Hisakazu, additional, Matsuoka, Ken‐ichi, additional, Otsuka, Fumio, additional, Maeda, Yoshinobu, additional, and Fujii, Nobuharu, additional

Published
2023
Full Text
View/download PDF

7. Benefit of prednisolone alone in nodal peripheral T-cell lymphoma with T follicular helper phenotype

Author

Kitamura, Wataru, Kobayashi, Hiroki, Urata, Tomohiro, Sato, Yumiko, Naoi, Yusuke, Yoshino, Tadashi, Maeda, Yoshinobu, and Kuyama, Shoichi

Subjects
immune thrombocytopenia, nodal peripheral T-cell lymphoma with T follicular helper phenotype, prednisolone, General Medicine
Abstract

A 71-year-old Japanese man presented with severe thrombocytopenia. A whole-body CT at presentation showed small cervical, axillary, and para-aortic lymphadenopathy, leading to suspicion of immune thrombocytopenia due to lymphoma. Biopsy was difficult to perform because of severe thrombocytopenia. Thus, he received prednisolone (PSL) therapy and his platelet count gradually recovered. Two and a half years after PSL therapy initiation, his cervical lymphadenopathy slightly progressed without other clinical symptoms. Hence, a biopsy from the left cervical lymph node was performed, and he was diagnosed with nodal peripheral T-cell lymphoma (PTCL) with T follicular helper (TFH) phenotype. Due to various complications, we continued treatment with prednisolone alone after the diagnosis of lymphoma; however, there was no further increase in lymph node enlargement and no other lymphoma-related symptoms for one and a half years after diagnosis. Although immunosuppressive therapy has been reported to produce a response in some patients with angioimmunoblastic T-cell lymphoma, our experience suggests that a similar subset may exist in patients with nodal PTCL with TFH phenotype, which has the same cellular origin. Immunosuppressive therapies may constitute an alternative treatment option even in the era of novel molecular-targeted therapies, especially for elderly patients who are ineligible for chemotherapy.

Published
2023

8. Efficient granulocyte collection method using high concentrations of medium molecular weight hydroxyethyl starch

Author

Kondo, Takumi, primary, Fujii, Keiko, additional, Fujii, Nobuharu, additional, Sumii, Yuichi, additional, Urata, Tomohiro, additional, Kimura, Maiko, additional, Matsuda, Masayuki, additional, Ikegawa, Shuntaro, additional, Washio, Kana, additional, Fujiwara, Hideaki, additional, Asada, Noboru, additional, Ennishi, Daisuke, additional, Nishimori, Hisakazu, additional, Matsuoka, Ken‐ichi, additional, Otsuka, Fumio, additional, and Maeda, Yoshinobu, additional

Published
2023
Full Text
View/download PDF

11. Pre-infusion factors predicting early failure after tisagenlecleucel for patients with relapsed/refractory diffuse large B-cell lymphoma: A single institute retrospective analysis

Author

Kitamura, Wataru, primary, Fujii, Nobuharu, additional, Kamoi, Chihiro, additional, Urata, Tomohiro, additional, Kobayashi, Hiroki, additional, Yamamoto, Akira, additional, Seike, Keisuke, additional, Fujiwara, Hideaki, additional, Asada, Noboru, additional, Ennishi, Daisuke, additional, Nishimori, Hisakazu, additional, Fujii, Keiko, additional, Matsuoka, Ken-ichi, additional, and Maeda, Yoshinobu, additional

Published
2023
Full Text
View/download PDF

13. Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan

Author

Urata, Tomohiro, primary, Sunami, Kazutaka, additional, Imai, Toshi, additional, Nawa, Yuichiro, additional, Hiramatsu, Yasushi, additional, Yamamoto, Kazuhiko, additional, Fujii, Soichiro, additional, Yoshida, Isao, additional, Yano, Tomofumi, additional, Naoi, Yusuke, additional, Ikeuchi, Kazuhiro, additional, Kobayashi, Hiroki, additional, Tani, Katsuma, additional, Momose, Shuji, additional, Tamaru, Jun-ichi, additional, Boyle, Merrill, additional, Jiang, Aixiang, additional, Sato, Yasuharu, additional, Yoshino, Tadashi, additional, Maeda, Yoshinobu, additional, Scott, David W., additional, and Ennishi, Daisuke, additional

Published
2022
Full Text
View/download PDF

14. Red blood cell depletion in small‐volume bone marrow processing using manipulation with third‐party red blood cells: A comparison of the performance of the COBE spectra and the spectra Optia systems

Author

Sumii, Yuichi, primary, Fujii, Nobuharu, additional, Fujii, Keiko, additional, Kondo, Takumi, additional, Urata, Tomohiro, additional, Kimura, Maiko, additional, Washio, Kana, additional, Fujiwara, Hideaki, additional, Asada, Noboru, additional, Ennishi, Daisuke, additional, Nishimori, Hisakazu, additional, Matsuoka, Ken‐ichi, additional, Otsuka, Fumio, additional, and Maeda, Yoshinobu, additional

Published
2022
Full Text
View/download PDF

15. Low hematocrit reduces the efficiency of CD34 + cell collection when using the Spectra Optia continuous mononuclear cell collection procedure

Author

Kondo, Takumi, primary, Fujii, Nobuharu, additional, Fujii, Keiko, additional, Sumii, Yuichi, additional, Urata, Tomohiro, additional, Kimura, Maiko, additional, Matsuda, Masayuki, additional, Ikegawa, Shuntaro, additional, Washio, Kana, additional, Fujiwara, Hideaki, additional, Asada, Noboru, additional, Ennishi, Daisuke, additional, Nishimori, Hisakazu, additional, Matsuoka, Ken‐ichi, additional, Otsuka, Fumio, additional, and Maeda, Yoshinobu, additional

Published
2022
Full Text
View/download PDF

18. Low hematocrit reduces the efficiency of CD34+ cell collection when using the Spectra Optia continuous mononuclear cell collection procedure.

Author

Kondo, Takumi, Fujii, Nobuharu, Fujii, Keiko, Sumii, Yuichi, Urata, Tomohiro, Kimura, Maiko, Matsuda, Masayuki, Ikegawa, Shuntaro, Washio, Kana, Fujiwara, Hideaki, Asada, Noboru, Ennishi, Daisuke, Nishimori, Hisakazu, Matsuoka, Ken‐ichi, Otsuka, Fumio, and Maeda, Yoshinobu

Abstract

Background: CD34+ cell collection efficiency (CE) is the determining factor when calculating processed blood volume (PBV) for leukapheresis (LP). However, the factors affecting CE in the continuous mononuclear cell collection (cMNC) protocol performed by the Spectra Optia apheresis system are not well established. Study Design and Methods: We retrospectively collected the data from 147 consecutive apheresis procedures across 106 healthy donors and 27 patients completed between July 2016 and December 2020 at the Okayama University Hospital. All procedures were performed using the Optia cMNC protocol. Results: The median CD34+ CE2 was significantly higher in the donor samples (64.3%) than in the patient samples (46.8%) (p <.0001). WBC counts, hematocrit, and platelet counts were all significantly higher in the donors than in the patients, and there was a moderate positive correlation between CD34+ CE2 and hematocrit (r =.47, p <.0001), with the equation of the line being y = 1.23x + 12.23. In contrast, there was only a very weak correlation between CD34+ CE2 and WBC or platelet count. In addition, low hematocrit correlated with an increased time to interface formation. Conclusion: These data revealed the negative impact of low hematocrit on the efficiency of CD34+ cell collection when using the Optia cMNC protocol and suggest that hematocrit values should also be considered when determining PBV. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

19. Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report

Author

Abe, Masaya, primary, Fujii, Nobuharu, additional, Mizuhara, Kentaro, additional, Urata, Tomohiro, additional, Sumii, Yuichi, additional, Fujiwara, Yuki, additional, Seike, Keisuke, additional, Sando, Yasuhisa, additional, Nakamura, Makoto, additional, Fujii, Keiko, additional, Saeki, Kyosuke, additional, Meguri, Yusuke, additional, Asada, Noboru, additional, Ennishi, Daisuke, additional, Nishimori, Hisakazu, additional, Matsuoka, Ken-ichi, additional, and Maeda, Yoshinobu, additional

Published
2021
Full Text
View/download PDF

24. CD79 Expression Is Associated with Cell-of-Origin and Outcome in Diffuse Large B-Cell Lymphoma

Author

Naoi, Yusuke, Chijimatsu, Ryota, Urata, Tomohiro, Sunami, Kazutaka, Imai, Toshi, Nawa, Yuichiro, Hiramatsu, Yasushi, Yamamoto, Kazuhiko, Fujii, Soichiro, Yoshida, Isao, Yano, Tomofumi, Ikeuchi, Kazuhiro, Kobayashi, Hiroki, Tani, Katsuma, Murakami, Hiroyuki, Ujiie, Hideki, Sato, Yasuharu, Takata, Katsuyoshi, Boyle, Merrill, Jiang, Aixiang, Maeda, Yoshinobu, Scott, David W., and Ennishi, Daisuke

Abstract

Introduction: CD79B is a target of polatuzumab vedotin, an antibody-drug conjugate, which significantly improved the prognosis of both previously untreated and relapsed/refractory patients with diffuse large B-cell lymphoma (DLBCL). However, the biological and clinical significance of CD79B protein and gene expression have not been fully explored in DLBCL, thus we aimed at examining these relationships.

Published
2023
Full Text
View/download PDF

31. Recurrent Cerebral Hemorrhaging with Platelet Dysfunction Accompanied by Anti-glycoprotein VI Autoantibodies in a Patient with TAFRO Syndrome.

Author

Yamamoto A, Nishimori H, Shirai T, Takano K, Komura A, Kambara Y, Fukumi T, Urata T, Asada N, Ennishi D, Fujii K, Fujii N, Matsuoka KI, Niiya K, Suzuki-Inoue K, and Maeda Y

Subjects
Humans, Syndrome, Platelet Membrane Glycoproteins immunology, Cerebral Hemorrhage immunology, Cerebral Hemorrhage etiology, Cerebral Hemorrhage blood, Thrombocytopenia immunology, Thrombocytopenia blood, Fever immunology, Fever etiology, Female, Middle Aged, Male, Blood Platelet Disorders immunology, Blood Platelet Disorders complications, Blood Platelet Disorders blood, Autoantibodies blood, Autoantibodies immunology, Recurrence
Abstract

Thrombocytopenia, anasarca, fever, renal dysfunction, and organomegaly (TAFRO) syndrome is an inflammatory disorder with an unclear pathogenesis. We herein report a case of TAFRO syndrome in remission in a patient who experienced recurrent intracranial bleeding despite a normal platelet count and coagulation system. A further investigation suggested the presence of anti-glycoprotein VI (GPVI) autoantibodies in the plasma, which induced platelet dysfunction and bleeding tendency. No new bleeding or relapse of TAFRO syndrome occurred after immunosuppressive therapy was initiated. These findings may help elucidate the autoimmune pathogenesis of TAFRO syndrome.

Published
2024
Full Text
View/download PDF

32. Comparison of serum sIL-2R and LDH levels in patients with intravascular large B-cell lymphoma and patients with advanced stage diffuse large B-cell lymphoma.

Author

Hirami Y, Nishimura MF, Urata T, Morimoto M, Maekawa Y, Yoshino T, Nishimura Y, and Sato Y

Subjects
Humans, Tumor Microenvironment, Receptors, Interleukin-2, Lymphoma, Large B-Cell, Diffuse pathology
Abstract

Intravascular large B-cell lymphoma (IVL) is a rare type of lymphoma characterized by tumor growth selectively within the vessels. The 5 th edition of the World Health Organization classification defines IVL as a large B-cell lymphoma, the same as diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). Since the clinical manifestations of IVL are nonspecific, the diagnosis is time-consuming, and the course is often fatal. Serum soluble interleukin-2 receptor (sIL-2R) and serum lactate dehydrogenase (LDH) levels are known to be elevated in a variety of lymphomas. However, the mechanism of sIL-2R elevation in B-cell lymphomas is not fully understood. In this study, we analyzed the serum level of laboratory findings, including sIL-2R and LDH, as well as the presence of B symptoms in 39 patients with IVL, and compared them with 56 patients with stage IV DLBCL. Both sIL-2R and LDH levels were significantly higher in IVL than in DLBCL (p = 0.035 and p = 0.002, respectively). In IVL, there were no significant differences in both sIL-2R and LDH levels between patients with and without B symptoms (p = 0.206 and p = 0.441, respectively). However, in DLBCL, both sIL-2R and LDH levels were significantly higher in the presence of B symptoms (p = 0.001 and p < 0.001, respectively). The high sIL-2R and LDH levels in IVL may be related to the peripheral blood microenvironment, but further studies are needed to verify this.

Published
2023
Full Text
View/download PDF

33. A novel method of identifying genetic mutations using an electrochemical DNA array.

Author

Wakai J, Takagi A, Nakayama M, Miya T, Miyahara T, Iwanaga T, Takenaka S, Ikeda Y, Amano M, and Urata T

Subjects
Ferrous Compounds chemistry, Humans, Imides chemistry, Lipoprotein Lipase genetics, DNA Mutational Analysis methods, Electrochemistry methods, Oligonucleotide Array Sequence Analysis methods
Abstract

We describe the development of a new type of DNA array chip that utilizes electrochemical reactions and a novel method of simultaneously identifying multiple genetic mutations on an array chip. The electrochemical array (ECA) uses a threading intercalator specific to double-stranded nucleotides, ferrocenylnaphthalene diimide (FND), as the indicator. ECA does not require target labeling, and the equipment is simple, durable and less expensive. The simultaneous multiple mutation detection (SMMD) system using an ECA chip and FND utilizes an enzyme to simultaneously distinguish several genetic mutations such as single nucleotide polymorphism (SNP), insertion, deletion, translocation and short tandem repeat. We examined this SMMD system using an ECA chip, by detecting seven different mutations on the lipoprotein lipase (LPL) gene for 50 patients in a blind test. It turned out that all the results obtained were concordant with the sequencing results, demonstrating that this system is a powerful tool for clinical applications.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results